Shuttle Pharmaceuticals (SHPH) vs Zhengye Biotechnology (ZYBT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Zhengye Biotechnology (ZYBT) has outperformed Shuttle Pharmaceuticals (SHPH) over the past year, losing 62.7% versus a loss of 87.4%. Zhengye Biotechnology is the larger company by market cap ($55.0 million vs $25.7 million), about 2.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SHPH | ZYBT |
|---|---|---|
| Share price | $5.40 | $1.16 |
| Market cap | $25.73M | $54.97M |
| 1-day change | -2.79% | +0.88% |
| YTD return | -69.17% | -0.01% |
| 1-year return | -87.36% | -62.67% |
| EPS (TTM) | $-16.87 | $-0.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $55.90 | $8.01 |
| 52-week low | $2.58 | $0.616 |
| Distance from 52-week high | -90.34% | -85.52% |
| Average volume | 1.36M | 5.10M |
| Shares outstanding | 4.76M | 47.39M |
| Employees | 2 | 269 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Zhengye Biotechnology is about 2.1 times larger than Shuttle Pharmaceuticals by market value ($54.97M vs $25.73M).
- ZYBT has outperformed SHPH by 24.7 percentage points over the past year.
About Shuttle Pharmaceuticals
SHPH stock →Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to treat cancers. It owns a pharmaceutical software artificial intelligence (AI) driven platform for molecular discovery and early-stage drug development.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
About Zhengye Biotechnology
ZYBT stock →Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in the People's Republic of China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs, as well as monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine.
Health Care · Biotechnology: Pharmaceutical Preparations · 269 employees
SHPH vs ZYBT FAQ
Which is bigger, Shuttle Pharmaceuticals or Zhengye Biotechnology?
Zhengye Biotechnology (ZYBT) is larger, with a market capitalization of $54.97M compared with $25.73M for Shuttle Pharmaceuticals (SHPH).
Which stock has performed better over the past year, SHPH or ZYBT?
ZYBT returned -62.67% over the past 12 months, compared with -87.36% for SHPH (price return, excluding dividends). Past performance does not predict future results.
Are Shuttle Pharmaceuticals and Zhengye Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.